Will a 10‑day cyclic course of norethindrone (5 mg daily) produce a withdrawal bleed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Will Norethindrone 5 mg Daily for 10 Days Produce a Withdrawal Bleed?

Yes, a 10-day course of norethindrone 5 mg daily will produce a withdrawal bleed in most patients who have adequate endometrial estrogen exposure, with bleeding typically occurring 2-4 days after completing the course.

Expected Response and Timing

The withdrawal bleed response depends critically on the patient's underlying estrogen status:

  • In adequately estrogenized patients: Norethindrone 5 mg daily for 10 days will reliably induce withdrawal bleeding within 2-4 days of discontinuation 1
  • In hypoestrogenic patients: Absence of withdrawal bleeding indicates either outflow tract obstruction or insufficient endometrial estrogen priming 1

Multiple guidelines confirm norethindrone acetate 5 mg daily for 5-10 days as a standard progestin challenge regimen 1. The 10-day duration you're asking about falls within the recommended range and should provide adequate endometrial transformation to produce withdrawal bleeding.

Clinical Context and Interpretation

When Withdrawal Bleeding Occurs

This confirms:

  • Intact outflow tract (patent cervix and vagina)
  • Adequate endogenous estrogen exposure
  • Functional endometrium capable of responding to hormonal stimulation

Research demonstrates that 96% of women on tamoxifen (an estrogenic compound) experienced withdrawal bleeding after cyclical norethisterone, indicating an estrogenically primed endometrium 2.

When Withdrawal Bleeding Does NOT Occur

Consider these possibilities:

  • Hypoestrogenic state (most common in functional hypothalamic amenorrhea, premature ovarian insufficiency)
  • Outflow tract obstruction (Asherman syndrome, cervical stenosis, imperforate hymen)
  • Müllerian anomalies

Next steps if no bleeding occurs:

  1. Pelvic ultrasound to assess endometrial thickness and Müllerian tract integrity 1
  2. Consider MRI if structural abnormalities suspected 1
  3. Some clinicians repeat with a shorter 5-day course before pursuing imaging 1

Dosing Considerations

The 5 mg daily dose is well-established:

  • Standard progestin challenge: 5-10 mg daily for 5-10 days 1
  • Endometrial protection in HRT: 5 mg daily for 12-14 days per 28-day cycle 3, 4
  • Menstrual suppression: Higher doses (10 mg daily) may be needed for continuous suppression 5

Common Pitfalls

Timing expectations: Patients should be counseled that bleeding typically begins 2-4 days after the last pill, not during the treatment course itself. Some patients may experience breakthrough bleeding during treatment, but this is less common with the 5 mg dose.

Tolerance issues: Progestins cause premenstrual-like symptoms in some patients (mood changes, bloating, fluid retention) 4. If poorly tolerated, micronized progesterone 200-300 mg daily for 10 days is an alternative 1.

Follow-up timing: If no withdrawal bleed occurs within 2-3 weeks, proceed with ultrasound evaluation rather than waiting indefinitely 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.